Skip to main content
SpringerLink
Log in

Liver Transplantation for HCC Beyond Milan

  • Liver Transplantation (D Mulligan, Section Editor)
  • Published:
Current Transplantation Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

To describe how the field of liver transplantation (LT) for hepatocellular carcinoma (HCC) has expanded beyond the Milan criteria.

Recent Findings

The Milan criteria have been the gold standard selection tool for patients with HCC undergoing LT since 1996. However, soon after its creation, the tumor size and number limits imposed by the Milan criteria were expanded upon by new models, such as the University of California-San Francisco criteria and the Metroticket. Still, these models were always limited by radiological inaccuracy in measuring tumor size and number and, more importantly, did not include any measurement of tumor behavior. Biomarkers, such as alpha-fetoprotein and neutrophil-lymphocyte ratio, provide that missing link and act as effective predictors of biological behavior and, therefore, provide an ability to predict tumor recurrence in patients undergoing LT for HCC, allowing for successful expansion beyond Milan.

Summary

More recently, newer scoring systems combine morphometric tumor data with markers of biology. These scoring systems, such as the MORAL score, AFP model, RETREAT score, and Metroticket 2.0, are providing the most accurate pre-LT assessments for HCC recurrence and hold the key to the continued improvement of LT outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg. 1985;202(4):401–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.

    Article  CAS  PubMed  Google Scholar 

  3. UNOS/OPTN policy 3.6.4.4.

  4. Ha J, Yan M, Aguilar M, Tana MM, Liu B, Frenette CT, et al. Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol. 2016;50(5):423–30.

    PubMed  Google Scholar 

  5. Sotiropoulos GC, Malag M, Molmenti E, Paul A, Nadalin S, Brokalaki E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation. 2005;79(4):483–7.

    Article  PubMed  Google Scholar 

  6. Shah SA, JCC T, ID MG, Cattral MS, Cleary SP, Levy GA, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006;81(12):1633–9.

    Article  PubMed  Google Scholar 

  7. Schwartz ME, D’Amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: are the Milan criteria still valid? Eur J Surg Oncol. 2008;34:256–62.

  8. Young RS, Aldiwani M, Hakeem AR, Nair A, Guthrie A, Wyatt J, et al. Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB. 2013;15(6):418–27.

    Article  PubMed  Google Scholar 

  9. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.

    Article  CAS  PubMed  Google Scholar 

  10. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.

    Article  PubMed  Google Scholar 

  11. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant. 2014;20(8):937–44.

    Article  Google Scholar 

  12. Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014;60(6):1957–62.

    Article  PubMed  Google Scholar 

  13. •• Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, et al. Recurrence after liver transplantation for hepatocellular carcinoma. Ann Surg. 2017;265(3):557–64 The MORAL score—a combination of pre- and post-LT criteria consisting of NLR, maximum AFP > 200, and largest tumor size along with pathologic and morphometric data—accurately predicted HCC recurrence post-LT.

    Article  PubMed  Google Scholar 

  14. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018 Jan;154(1):128–39.

    Article  PubMed  Google Scholar 

  15. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11):2587–96.

    Article  CAS  PubMed  Google Scholar 

  16. Mazzaferro V. Results of liver transplantation: with or without Milan criteria? Liver Transplant. 2007;13(11 SUPPL. 2).

  17. Bittermann T, Niu B, Hoteit MA, Goldberg D. Waitlist priority for hepatocellular carcinoma beyond Milan criteria: a potentially appropriate decision without a structured approach. Am J Transplant. 2014;14(1):79–87.

    Article  CAS  PubMed  Google Scholar 

  18. D’Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transplant. 2009;15(10):1278–87.

    Article  Google Scholar 

  19. Lei JY, Wang WT, Yan LN. “Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol. 2013;19(44):8093–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Abelev GI. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res. 1971;14(C):295–358.

    Article  CAS  PubMed  Google Scholar 

  21. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34(4):603–5.

    Article  CAS  PubMed  Google Scholar 

  22. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

    Article  PubMed  Google Scholar 

  23. Sherman M. The resurrection of alphafetoprotein. J Hepatol. 2010;52(6):939–40.

    Article  CAS  PubMed  Google Scholar 

  24. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transplant. 2013;19(6):634–45.

    Article  Google Scholar 

  25. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64(6).

  26. Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, et al. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2015;38(10):2698–707.

    Article  Google Scholar 

  27. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10(1):129–37.

    Article  CAS  PubMed  Google Scholar 

  28. Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschênes M, et al. Pretransplantation α-fetoprotein slope and Milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation. 2013;95(1):228–33.

    Article  CAS  PubMed  Google Scholar 

  29. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55(4):814–9.

    Article  CAS  PubMed  Google Scholar 

  30. Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016;22:262–74.

  31. Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012;10(4):428–33.

    Article  CAS  PubMed  Google Scholar 

  32. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Vol. 106, Journal of the National Cancer Institute. 2014.

  33. Halazun KJ, Hardy MA, Rana AA, Woodland DC, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141–51.

    Article  PubMed  Google Scholar 

  34. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64.

    Article  CAS  PubMed  Google Scholar 

  35. Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, et al. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res. 2013;43(7):709–16.

    Article  PubMed  Google Scholar 

  36. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

    Article  CAS  PubMed  Google Scholar 

  37. Xia W, Ke Q, Wang Y, Wang W, Zhang M, Shen Y, et al. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation. World J Surg Oncol. 2015;13(1):60.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Xia W, Ke Q, Guo H, Wang W, Zhang M, Shen Y, et al. Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio. BMC Cancer. 2017;17(1):14.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Zheng S-S, Xu X, Wu J, Chen J, Wang W-L, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726–32.

    Article  CAS  PubMed  Google Scholar 

  40. Castell JV, Gómez-lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12(5):1179–86.

    Article  CAS  PubMed  Google Scholar 

  41. Zheng Z, Zhou L, Gao S, Yang Z, Yao J, Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci. 2013;10(6):653–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transplant. 2012;18(12):1406–14.

    Article  Google Scholar 

  43. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo K-J, Lee S-D, et al. Des-γ-Carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–31.

    Article  CAS  PubMed  Google Scholar 

  44. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37(5):1114–21.

    Article  CAS  PubMed  Google Scholar 

  45. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;9(10):2362–71.

    Article  CAS  PubMed  Google Scholar 

  46. Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62(4):848–54.

    Article  CAS  PubMed  Google Scholar 

  47. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, Aishima SI, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma - with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95(3):235–40.

    Article  CAS  PubMed  Google Scholar 

  48. Sakaguchi T, Suzuki S, Morita Y, Oishi K, Suzuki A, Fukumoto K, et al. Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria. Surg Today. 2010;40(7):638–45.

    Article  PubMed  Google Scholar 

  49. Pommergaard H-C, Burcharth J, Rosenberg J, Rasmussen A. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysis. Transplant Rev. 2016;30(3):171–7.

    Article  Google Scholar 

  50. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of milan criteria. Gastroenterology. 2012;143(4).

  51. Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–9.

    Article  PubMed  Google Scholar 

  52. Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, et al. Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int. 2016;36(11):1657–67.

    Article  CAS  PubMed  Google Scholar 

  53. • Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3(4):193–500 The RETREAT score combined AFP level, microvascular invasion, sum of the largest viable tumor diameter, and nuber to accurately predict recurrence post-LT, stratifying patients from low-risk (3%) to high-risk (75%).

    Article  Google Scholar 

  54. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2017.

  55. • Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-Uso T, Quintini C, et al. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Lancet Gastroenterol Hepatol. 2017;2(8):595–603 The HALT-HCC score combined MELD-Na, tumor burden score, and ln AFP to accurately predict HCC recurrence after LT.

    Article  PubMed  Google Scholar 

  56. Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CDL, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Paolo Magistri and Russell Rosenblatt contributed equally to this work.

Authors and Affiliations

  1. Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy

    Paolo Magistri

  2. Department of Gastroenterology and Hepatology, Weill Cornell Medicine College, New York, NY, USA

    Russell Rosenblatt

  3. Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Weill Cornell Medical College, New York, NY, USA

    Karim J. Halazun

Authors
  1. Paolo Magistri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell Rosenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karim J. Halazun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karim J. Halazun.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Liver Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Magistri, P., Rosenblatt, R. & Halazun, K.J. Liver Transplantation for HCC Beyond Milan. Curr Transpl Rep 5, 319–326 (2018). https://doi.org/10.1007/s40472-018-0212-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40472-018-0212-y

Keywords

Search

Navigation